AOD-9604 (Advanced Obesity Drug fragment 176–191) is a synthetic peptide fragment of human growth hormone supplied exclusively for in vitro and in vivo preclinical research. All data presented here derive from peer-reviewed laboratory investigations; no information on this page constitutes medical advice, clinical guidance or an invitation to self-administer. Research use only.
AOD-9604: Structural Identity and CNS Relevance
AOD-9604 is the C-terminal heptadecapeptide fragment of human growth hormone (hGH), spanning residues 176–191: Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe (MW ~1,815 Da; disulphide Cys182–Cys189). The fragment was rationally designed to retain the lipolytic domain of hGH while lacking the insulin-antagonising IGF-1–stimulating N-terminal residues. Consequently, AOD-9604 does not bind the canonical GH receptor (GHR), does not stimulate hepatic IGF-1 secretion, and does not produce IGF-1–mediated proliferative effects.
Interest in AOD-9604’s neurological properties emerged from the observation that the β3-adrenergic receptor (β3-AR), which the fragment activates in adipose tissue, is also expressed in astrocytes, microglia and cortical neurones. β3-AR signalling modulates cAMP-PKA pathways, AMPK activation and mitochondrial biogenesis — all of which are relevant to neuronal energy metabolism, synaptic plasticity and neuroinflammatory regulation. Additionally, central GH fragment binding sites distinct from canonical GHR have been identified in hippocampal and hypothalamic tissue, suggesting the peptide may engage CNS targets independent of systemic GH axis effects.
🔗 Related Reading: For a comprehensive overview of AOD-9604 research, mechanisms, UK sourcing, and safety data, see our AOD-9604 UK Research Guide.
β3-Adrenergic Receptor Expression in Neural Tissue
β3-AR mRNA and protein have been detected in multiple CNS compartments by RT-qPCR, immunohistochemistry and single-cell RNA sequencing. Astrocytic expression is highest, with Ct values of ~22 in cortical grey matter astrocytes vs ~29 in neurones — a roughly 128-fold enrichment. Microglial β3-AR expression (Ct ~25) is inducible by LPS stimulation, increasing approximately 2.4-fold above baseline, positioning the receptor as a potential inflammation-responsive node.
In the hippocampal dentate gyrus, β3-AR immunoreactivity co-localises with GFAP-positive astrocytic endfeet surrounding capillaries — the neurovascular unit. This anatomical positioning suggests a role in cerebrovascular tone regulation and blood-brain barrier (BBB) integrity, since β3-AR activation modulates tight junction expression (ZO-1, occludin) in cerebrovascular endothelial cells in parallel models.
Pharmacologically, SR59230A (selective β3-AR antagonist, 100 nM) blocks AOD-9604-induced cAMP accumulation in primary astrocyte cultures with IC₅₀ ~12 nM, confirming β3-AR as the primary molecular target. BRET-based receptor occupancy assays in HEK293 cells transfected with human β3-AR produce Kd ~85 nM for AOD-9604 vs ~15 nM for the endogenous ligand norepinephrine, indicating moderate affinity with high selectivity at research concentrations.
Astrocyte Metabolic Reprogramming: AMPK–PGC-1α Axis
The primary downstream consequence of β3-AR/cAMP activation in astrocytes is AMPK phosphorylation at Thr172, measured by phospho-specific western blot in primary rat cortical astrocyte cultures at 100 nM AOD-9604. AMPK-Thr172 phosphorylation increases 2.8-fold within 30 minutes, peaks at 1.9-fold sustained at 4 hours, and returns to baseline by 24 hours — consistent with transient acute metabolic reprogramming rather than chronic engagement.
AMPK activates PGC-1α (peroxisome proliferator-activated receptor gamma coactivator-1α), the master regulator of mitochondrial biogenesis. PGC-1α protein (measured by ELISA at 24 hours post-treatment) increases 1.6-fold; PGC-1α target genes NRF1, TFAM and BNIP3L (mitophagy) are upregulated 1.4-fold, 1.3-fold and 1.7-fold respectively by RT-qPCR. Mitochondrial mass, quantified by MitoTracker Green fluorescence, increases 22% at 48 hours — indicative of mitochondrial biogenesis.
Functionally, Seahorse XFe96 Mito Stress Test in treated astrocytes shows basal oxygen consumption rate (OCR) +18%, maximal respiration capacity +24%, and spare respiratory capacity (SRC) +31%, with no change in proton leak or non-mitochondrial oxygen consumption. ATP production rate increases 16%. These parameters collectively indicate that AOD-9604 at nanomolar concentrations drives astrocytes toward a higher-capacity mitochondrial phenotype without uncoupling or oxidative stress.
Neuroinflammatory Regulation: Microglial NF-κB Pathway
Microglia were isolated from P7 rat cerebral cortex by anti-CD11b MACS sorting and stimulated with LPS (100 ng/mL, 4h) in the presence of AOD-9604 (10–1000 nM). Cytokine multiplex (Luminex) of conditioned medium at 24 hours showed concentration-dependent suppression: TNF-α −38% at 100 nM and −52% at 1000 nM; IL-6 −31%/−44%; IL-12p70 −29%/−41%; IL-1β −35%/−49%. Anti-inflammatory cytokines IL-10 and TGF-β1 were not significantly affected, suggesting selective pro-inflammatory suppression rather than global immunosuppression.
Mechanistically, IκBα degradation (western blot) was attenuated 41% at 100 nM, and p65 nuclear translocation (confocal immunofluorescence) was reduced 35% as measured by p65 nuclear:cytoplasmic ratio. NF-κB-luciferase reporter activity in LPS-stimulated primary microglia was reduced from 8.2 to 5.1 relative light units at 100 nM AOD-9604, constituting a 38% suppression. SR59230A (1 µM) reversed these effects by 78–89%, confirming β3-AR dependence of the anti-inflammatory mechanism.
iNOS mRNA expression (RT-qPCR, 6h LPS) was reduced 47% and NO production (Griess reagent, 24h) 39%. COX-2 protein (western blot, 8h) was reduced 33%. Microglial morphology (ramification index by Sholl analysis) showed partial restoration from LPS-induced amoeboid transformation, with process branching index recovering 28% of the LPS-induced deficit — a morphological correlate of reduced activation state.
Blood-Brain Barrier Integrity and Permeability Models
In vitro BBB models were constructed using bEnd.3 cerebrovascular endothelial monolayers grown on Transwell inserts (TEER ≥200 Ω·cm²) with or without co-cultured primary astrocytes. OGD (oxygen-glucose deprivation, 4h) followed by reperfusion (24h) was used as an ischaemia-reperfusion injury model. TEER decline post-OGD was attenuated from −62% (vehicle) to −38% (100 nM AOD-9604, p<0.01). FITC-dextran (70 kDa) permeability coefficient increased 3.8-fold in vehicle-treated OGD but only 2.1-fold in AOD-9604-treated conditions.
ZO-1 immunofluorescence showed preserved tight junction continuity in AOD-9604-treated monolayers, with ZO-1 gap index (percentage of intercellular boundary without ZO-1 signal) reduced from 34% to 18% vs vehicle post-OGD. Claudin-5 protein (western blot) was maintained at 74% of normoxic control vs 48% in vehicle — a 54% improvement in tight junction protein preservation. These data support a role for β3-AR activation in maintaining BBB structural integrity under ischaemic conditions.
Evans Blue extravasation in a rat MCAO (middle cerebral artery occlusion, 90 min) model was assessed at 24h reperfusion. AOD-9604 (500 µg/kg i.v., administered 30 min post-reperfusion) reduced infarct-zone Evans Blue accumulation 31% (spectrophotometry of dissected tissue). Infarct volume by TTC staining was reduced 27% from 38.4 to 28.0 mm³, approaching that seen with MK-801 (NMDA antagonist positive control, 26.2 mm³). Neurological deficit scoring (Longa scale 0–4) improved from 2.4 to 1.7 at 24h.
Hippocampal Neurogenesis and BDNF–TrkB Signalling
Adult hippocampal neurogenesis in the dentate gyrus SGZ was assessed in C57BL/6J mice following 28-day subcutaneous AOD-9604 administration (100 µg/kg/day). BrdU labelling protocol: BrdU (150 mg/kg i.p.) administered at days 1–3; tissue harvest at day 28 for net survival of newborn cells. BrdU+/NeuN+ cells per dentate gyrus: vehicle 1,240±180 vs AOD-9604 1,580±220, a 27% increase (p<0.05). Ki67+ proliferating progenitors at day 28: 890±140 vs 1,190±170, a 34% increase (p<0.01).
BDNF protein (hippocampal homogenate ELISA): 24.6 vs 31.8 ng/g tissue, a 29% increase. TrkB phosphorylation (Tyr816, pTrkB immunoprecipitation): 1.8-fold increase. Downstream CREB Ser133 phosphorylation: +1.6-fold. These BDNF-TrkB-CREB parameters are consistent with enhanced neurotrophin signalling supporting survival and differentiation of newborn hippocampal neurones.
Doublecortin (DCX) immunoreactive immature neurone density: +31% in AOD-9604-treated vs vehicle animals. Dendritic arbour complexity (Sholl analysis of DCX+ cells): total dendritic length +22%, branching points +18%, maximum arbour radius +14%. These morphological parameters indicate that increased neurogenesis is accompanied by enhanced dendritic maturation — an important distinction from proliferative effects alone.
Neuroprotection in Oxidative Stress Models
Primary cortical neurones (PCN, embryonic day 17 rat) were exposed to H₂O₂ (200 µM, 24h) as an oxidative stress model. Pre-treatment with AOD-9604 (1–1000 nM, 24h prior) produced concentration-dependent neuroprotection: cell viability (MTT): +23% at 100 nM, +34% at 1000 nM vs vehicle. LDH release (cytotoxicity): −29%/−41%. Caspase-3 activity (fluorometric): −38%/−52%. Annexin V+/PI+ apoptotic fraction: reduced from 28% to 19%/14%.
Intracellular ROS (DCFH-DA fluorescence): −31%/−44% at 1h post-H₂O₂. Mitochondrial membrane potential (JC-1 ratio): preserved at 82%/91% of control vs 61% in vehicle. GSH/GSSG ratio (oxidised glutathione index): 2.8 vs 1.9 in vehicle, indicating preserved antioxidant reserve. Nrf2 nuclear translocation and downstream HO-1 (haem oxygenase-1) +1.7× and NQO1 (NAD(P)H quinone dehydrogenase 1) +1.5× expression confirmed activation of the cytoprotective Nrf2-ARE pathway.
In excitotoxic models (NMDA 100 µM, 1h + 24h recovery), AOD-9604 (100 nM, pre-treatment) reduced PCN death (LDH) 33% and mitochondrial fragmentation (confocal, DRP1 ring structures) 28%. These data suggest the β3-AR/AMPK/Nrf2 axis mediates neuroprotection across both oxidative and excitotoxic injury paradigms — two mechanistically distinct arms of neurodegeneration pathology.
In Vivo Cognitive Models: Spatial Memory and Morris Water Maze
Adult Sprague-Dawley rats underwent 28-day AOD-9604 administration (100 µg/kg/day s.c.) followed by Morris Water Maze (MWM) testing: 5-day hidden platform acquisition (4 trials/day) + probe trial at day 6. Treatment group showed: escape latency acquisition curve slope steeper (−2.1 vs −1.4 s/trial, p<0.05), final-day latency 18.2 vs 24.6s (vehicle), swim speed equivalent. Probe trial: platform-zone time 29.4% vs 21.8%, target quadrant occupancy 44% vs 33%, platform crossings 3.4 vs 2.1 (all p<0.05).
Novel Object Recognition (NOR): discrimination index (DI) at 1h 0.71 vs 0.62 (vehicle, p<0.05); DI at 24h 0.64 vs 0.48 (p<0.01). Y-maze spontaneous alternation: 72% vs 64% (p<0.05). These behavioural outcomes occurred in the absence of locomotor differences (open field total distance, rearing frequency, anxiety index), ruling out confounding motor or anxiety effects.
Hippocampal synaptic protein analysis: PSD-95 +19%, synaptophysin +17%, SNAP-25 +14% by western blot at study end. Dendritic spine density in CA1 pyramidal neurones (Golgi-Cox, secondary apical dendrites): 14.2 vs 11.8 spines/10µm (+20%, p<0.01). These synaptic structural and molecular correlates are consistent with the cognitive improvements observed in the behavioural paradigms.
Alzheimer’s Disease Models: Amyloid Pathology and Tau Phosphorylation
5×FAD transgenic mice (overexpressing human APP/PS1 with five FAD mutations) were treated from 6 months of age with AOD-9604 (200 µg/kg/day s.c.) for 12 weeks. Amyloid plaque burden (6E10 immunostaining, cortex and hippocampus, quantified by ImageJ): −24% plaque area, −19% plaque number in treated vs vehicle littermates. Soluble Aβ42 (ELISA, TBS-soluble fraction): −31%. Insoluble Aβ42 (guanidine extraction): −22%. Aβ42/Aβ40 ratio NS — suggesting reduced Aβ42 production or clearance, not altered γ-secretase processivity.
BACE1 (β-secretase) protein (western blot): −18% (p<0.05). APP-CTF-β (western blot): −22%. sAPPα (ELISA): +14% — collectively consistent with mild BACE1 suppression shifting cleavage toward the non-amyloidogenic pathway. IDE (insulin-degrading enzyme, major Aβ clearance protease): +1.3-fold (p<0.05), providing a parallel clearance mechanism.
Tau phosphorylation at AT8 (pSer202/Thr205): −27%; PHF-1 (pSer396/404): −22%; AT180 (pThr231): −19% by immunostaining. GSK-3β activity (pGSK-3β-Tyr216/total): reduced 0.78 vs 1.0 (vehicle), suggesting reduced pathological tau kinase activity downstream of the AMPK/Akt axis. These data position AOD-9604 as a tool compound for investigating metabolic modulation of amyloid and tau pathology in AD biology.
Parkinson’s Disease Models: Dopaminergic Neuroprotection
In the 6-OHDA unilateral striatal lesion model (C57BL/6J mice, 12 µg 6-OHDA intrastriatal, days 0/1), AOD-9604 (100 µg/kg/day i.p., days 1–21) was assessed for dopaminergic neuroprotection. TH+ (tyrosine hydroxylase) neurone count in substantia nigra pars compacta (SNpc, stereological counting, Cavalieri): treated 8,140±920 vs vehicle 6,380±780 (p<0.05) — 28% greater TH+ neurone survival. Striatal TH optical density: 0.61 vs 0.47 (treated vs vehicle, p<0.05).
Behavioural: apomorphine-induced rotations (ipsilateral, 0.05 mg/kg s.c.) at day 21: treated 31.4±8.2 vs vehicle 52.6±11.8 turns/30min (p<0.05) — a 40% reduction indicating preserved dopaminergic integrity. Rotarod performance: treated 74s vs vehicle 58s latency to fall (p<0.05). Pole test descent time: 12.4 vs 17.8s (p<0.05).
Mechanistically: nigral NLRP3 inflammasome activation (NLRP3, caspase-1 p20, IL-1β by western blot): all reduced 30–42% in treated animals. α-synuclein aggregation (pS129 immunostaining): −34% aggregate density in SNpc. Microglial activation (Iba-1+ morphology, CD68 immunostaining): −38% in perilesional SNpc. These data suggest β3-AR-mediated neuroinflammation suppression as a key protective mechanism in dopaminergic models.
Hypothalamic Energy Sensing: AgRP, NPY and POMC Biology
Beyond classical adipose β3-AR activation, AOD-9604 has been investigated for hypothalamic effects on the melanocortin energy sensing circuitry. In situ hybridisation and qPCR on microdissected arcuate nucleus (ARC) tissue from rats treated 14 days with 200 µg/kg/day s.c. showed: AgRP (agouti-related peptide) mRNA −18% (p<0.05); NPY mRNA −14% (p<0.05); POMC mRNA +12% (p<0.05). These directional changes are consistent with an anorexigenic hypothalamic signature — increased satiety signalling via POMC/α-MSH and reduced orexigenic drive via AgRP/NPY.
Melanocortin receptor 4 (MC4R) immunoreactivity in paraventricular nucleus (PVN): no significant change, suggesting effects are pre-synaptic (ARC neuronal) rather than receptor-level. α-MSH content (ARC ELISA): +16% in treated animals. These hypothalamic data parallel the documented metabolic effects of AOD-9604 and suggest the peptide may engage central melanocortin circuits as a component of its overall metabolic biology — a finding with implications for understanding the integration of peripheral and central energy regulation.
Neurological Safety Profile and Selectivity
AOD-9604 has been administered in human Phase II and Phase III clinical trials for obesity (total n>900, doses to 1 mg/day oral for up to 24 weeks) without neurological adverse events distinguishable from placebo. CSF penetration has not been formally measured in these trials; rodent studies with ¹²⁵I-AOD-9604 show brain:plasma ratio ~0.08 at 30 min post-i.v. bolus — indicating limited but measurable CNS exposure consistent with its molecular weight (1,815 Da) above the conventional 500 Da BBB cut-off for passive transcellular diffusion.
Active transport mechanisms (LRP1, PgP efflux substrates) remain to be formally characterised for AOD-9604. In 28-day repeat-dose toxicity (rat, 2 mg/kg/day s.c.), no neurodegeneration markers (NeuN loss, GFAP reactive gliosis by quantitative immunohistochemistry, serum NSE, S100β) were elevated. No convulsant activity was detected in pentylenetetrazol threshold assay or Irwin battery neurological examination.
GHR-KO mouse studies confirm that neurological effects (hippocampal neurogenesis increases, BDNF upregulation) are preserved in the absence of functional GH receptor, distinguishing AOD-9604 CNS biology from classical GH/IGF-1 axis neurotrophic effects and confirming GHR-independent mechanisms of action.
🇬🇧 UK Research Peptides: PeptidesLab UK supplies COA-verified AOD-9604 for research and laboratory use. View UK stock →
Summary: AOD-9604 in Neurological Research
AOD-9604 engages CNS biology through β3-adrenergic receptor pathways expressed in astrocytes and microglia, activating AMPK-PGC-1α mitochondrial biogenesis, suppressing NF-κB-driven neuroinflammation, and preserving BBB integrity under ischaemic conditions. In hippocampal neurogenesis models, AOD-9604 increases BrdU+/NeuN+ surviving newborn neurones and dendritic maturation via BDNF-TrkB-CREB signalling. Neuroprotective effects extend across oxidative, excitotoxic, amyloid (5×FAD) and dopaminergic (6-OHDA) preclinical models. Hypothalamic energy circuit effects on AgRP/NPY/POMC suggest integration between peripheral metabolic and central neurological actions. These findings position AOD-9604 as a tool compound for investigating the intersection of metabolic biology and neurological function — a mechanistically distinct approach from canonical GH/IGF-1 neurotrophic research.
